Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer
about
Metabolic complications of androgen deprivation therapy for prostate cancerImpact of Diet-Induced Obesity and Testosterone Deficiency on the Cardiovascular System: A Novel Rodent Model Representative of Males with Testosterone-Deficient Metabolic Syndrome (TDMetS)A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patientsCare of the cancer survivor: metabolic syndrome after hormone-modifying therapy.Weight control and cancer preventive mechanisms: role of insulin growth factor-1-mediated signaling pathwaysClinical significance of androgen secretion disorders in men with a malignancy.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Prostate cancer: How can we improve the health of men who receive ADT?Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation OncologyGonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksMetabolic effects of androgen deprivation therapyMetabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer.Acute testosterone deprivation reduces insulin sensitivity in menThe effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review.Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancerThe Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate CancerAndrogen-deprivation therapy and risk for biliary disease in men with prostate cancerTestosterone and metabolic syndrome: The link.Effects of resistance exercise in prostate cancer patients: a meta-analysis.Androgen deprivation therapy toxicity and management for men receiving radiation therapyNew players for advanced prostate cancer and the rationalisation of insulin-sensitising medicationGonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancerGroup-based exercise in daily clinical practice to improve physical fitness in men with prostate cancer undergoing androgen deprivation therapy: study protocol.Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks.Effects of transdermal testosterone treatment on inflammatory markers in elderly males.Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancerImpact of androgen deprivation therapy on cardiovascular disease and diabetes.Emerging cardiometabolic complications of androgen deprivation therapy.Testosterone and obesity.Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.Metabolic syndrome in prostate cancer: impact on risk and outcomesThe use of exercise interventions to overcome adverse effects of androgen deprivation therapy.The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients.Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy.[Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
P2860
Q24616159-A4855574-4979-4DFB-ADF8-5DA5E61DB2D3Q27318055-3A9D9F88-5CB0-4EB0-B5AF-03F8C5D91821Q28076622-85758FBC-C1DF-432E-8659-2EEB3E4317BFQ33649441-41B0B238-6F8D-48C6-BCEF-5D3D59253224Q33724772-9207B842-B430-41E4-A7D1-48C6EE9CC12BQ33840617-6D8697E4-BC5A-46C2-9E15-32FA0AF87BAAQ33977523-D64E3A03-A7B7-4DBC-8BE0-4482A123DEE8Q33978336-84374AED-813C-4396-B74C-EE5A7A4FCD13Q34421944-9B4CE2BB-EC85-429D-8D60-65C1DB0B1164Q34505196-59C94AD0-B241-4754-BD6B-AA0C721BF2AAQ34617897-EA38A2D8-64BF-4431-9318-8263284D62A2Q34617924-907FC646-C89E-47D5-999E-F93CDC233DEFQ34960686-807310B2-09E2-4E26-BE93-34D3D28A8B30Q34962416-696FF879-C6FF-45F4-91F1-30571C8DE591Q35433102-3ED49C64-FDB8-45FB-844B-43B5B14F5962Q35573457-773A2108-558A-42A2-88E8-40D41E83152AQ35640064-00A5A8BE-1548-4450-A864-2653C40358C8Q35689824-6CB478D3-D097-4C12-9639-7B8E38C5A707Q35776240-1608E9A7-4635-449D-8DDF-C95FA449A84EQ35882782-E3C21EEB-B6EC-4C7A-88B0-A04458FA4345Q35951635-1B317CFD-4DD3-402F-832C-D717A0D25A45Q35968107-16072B46-6D9A-486D-BE26-640E719EB48BQ36397349-962FBCB5-5403-4B77-9273-60B7D7340539Q36530136-23D4FB09-4423-4B77-94A7-413022CF7A53Q36734036-4AC306BF-CA61-46ED-BA70-51DB704ACD24Q36898849-208C25E9-2F49-4063-9F6B-B4765FF2145FQ37063622-A16EE65B-1C94-465D-8AD5-6F522DFC318AQ37085223-0C6F6B52-754A-4BF1-BF3B-3298EB684B91Q37234333-DEAA40CE-9EC6-465F-A9C9-D2114E704A35Q37390104-8516B97C-79E4-446C-A67E-437F87A4DEDCQ37394248-81D7BC6B-F7E5-46FD-8B56-97B232B51D3AQ37583719-F0F6E475-DA02-4E16-AE1F-1EF400DC1855Q37690775-B712E27C-FA96-4B5F-842A-B3CFBB8C55D0Q38485746-9B52455E-218F-40B8-92D3-5A563AFED548Q38707724-6F461F29-6511-42CE-9CD1-950EF4945B9CQ38805127-F6AFCC13-551F-445E-827C-1F835A43AB44Q38817011-9EB22AE7-1569-4992-A62A-39A904622667Q39032205-78F876E3-C3A9-4D31-903F-A53AD81E8A35Q39972993-F32D5B24-A1C4-40CA-9BC2-FC944C8B5F89Q40797796-7DCC60C0-3BA2-4D31-AA79-F7D1346882CD
P2860
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adipocytokines, obesity, and i ...... n blockade for prostate cancer
@en
Adipocytokines, obesity, and i ...... blockade for prostate cancer.
@nl
type
label
Adipocytokines, obesity, and i ...... n blockade for prostate cancer
@en
Adipocytokines, obesity, and i ...... blockade for prostate cancer.
@nl
prefLabel
Adipocytokines, obesity, and i ...... n blockade for prostate cancer
@en
Adipocytokines, obesity, and i ...... blockade for prostate cancer.
@nl
P2093
P2860
P1433
P1476
Adipocytokines, obesity, and i ...... n blockade for prostate cancer
@en
P2093
David M Nathan
Mary Anne Fallon
Matthew R Smith
P2860
P304
P356
10.1016/J.UROLOGY.2007.08.035
P407
P577
2008-02-01T00:00:00Z